Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04

Posted on August 4, 2026August 5, 2026 By K-STOCK Editor No Comments on [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Following its bonus issue, an ex-rights adjustment for ALTEOGEN common stock will take effect on August 5, 2026, with an ex-rights base price set at KRW 267,000.

📊 [Key Disclosure Details & Major Figures Summary]

  • Company Name: ALTEOGEN (Short Code: A196170)
  • Share Type: Common Stock
  • Ex-Rights Effective Date: August 05, 2026
  • Base Price: KRW 267,000
  • Reason: Bonus Issue

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Ex-Rights Base Price Application and New Share Allotment/Listing Schedule

This disclosure reports the ex-rights effective date (August 5, 2026) and base price resulting from the bonus issue. Verifying that the ex-rights base price is correctly applied on the effective date and tracking the upcoming new share allotment and listing schedules is essential because it allows investors to confirm the stock price adjustment and clear timelines for receiving new shares. Detailed information can be cross-checked in the previously filed ‘Decision on Bonus Issue’ and related notice disclosures.

📢 Disclaimer & Source Notice

Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04
Next Post: [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05

Related Posts

[Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2025-04-24 Disclosures
[Disclosure] Samsung Biologics (207940) – (Correction) Submission of Audit Report / 2024-02-28 Disclosures
[Disclosure] SK hynix (000660) – Decision on Business Acquisition (Correction Disclosure) / 2026-03-03 Semiconductors
[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2025-09-15 Disclosures
[Disclosure] SK Square (402340) – Treasury Stock Disposal Decision / 2025-04-24 Semiconductors
[Disclosure] Hanwha Ocean (042660) – (Correction) Execution of Sales / Supply Contract / 2026-03-31 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme